Further investigations will facilitate a deeper understanding of the precise mechanism by which FCGR2A contributes to the pathogenesis of inflammatory bowel disease, as well as explore its potential as a viable therapeutic target for enhancing patient clinical outcomes and quality of life. This evidence concerns the gene FCGR2A and inflammatory bowel disease.